3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
OTHER
3
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
5
Neoplasms
3
Polycystic Ovary Syndrome
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Triple Negative Breast Neoplasms
1
TP53 Y220C Mutation
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor, Adult
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Insulin Resistance
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Drug-drug Interaction,SHR3680
1
Diabetes Mellitus, Type 2
1
Colonic Neoplasms
1
Breast Diseases
1
Brain Neoplasms
1
Advanced Solid Malignancies
1
Interventions
Bevacizumab
27
Leucovorin
23
Fluorouracil
22
Oxaliplatin
17
Irinotecan
15
Cetuximab
14
pembrolizumab
11
IFL protocol
11
Panitumumab
10
Folfox protocol
10
Capecitabine
10
Gemcitabine
7
adagrasib
5
Cisplatin
5
Carboplatin
5
Ramucirumab
4
Colonoscopy
4
veliparib
3
spartalizumab
3
selpercatinib
3
regorafenib
3
labetuzumab
3
durvalumab
3
conatumumab
3
cemiplimab
3
Pemetrexed
3
Paclitaxel
3
HMPL-013
3
Drug Therapy
3
5,11-methenyltetrahydrohomofolate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Colonic Neoplasms
×
Metformin
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn